

Special Issue

Recent Advances in Therapeutic Cancer Vaccines

Message from the Guest Editors

Cancer has always been one of the leading causes of death worldwide. The prevention and treatment of cancer are important means to reduce the incidence of tumors and prolong the lives of patients. In recent years, the results of tumor immunotherapy in basic research and clinical research have attracted much attention. Many vaccines for the treatment of cancer have achieved amazing effects when used alone or in combination with other traditional cancer treatment methods, indicating that they have great clinical application potential. With the elucidation of the underlying mechanisms of cancer immunomodulation, effective, controllable and durable cancer vaccines will play an important role in cancer treatment, prolonged survival and recurrence and cancer prevention. This Special Issue encourages submissions related to the progress and development of cancer vaccine research and clinical application of cancer immunity, in order to explore the obstacles in cancer vaccine research and promote the efficacy of cancer vaccines. At the same time, it also aims to discuss the future development and prospects of therapeutic cancer vaccines.

Guest Editors

Dr. Manisha Singh

Department of Genomic Medicine, Division of Cancer Medicine,
University of Texas MD Anderson Cancer Center, Houston, TX 77030,
USA

Dr. Shweta Dubey

Amity Institute of Virology and Immunology (AIVI), Amity University,
Noida, India

Deadline for manuscript submissions

closed (31 May 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/104960

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).